Scope of the Report:
This report focuses on the Sorafenib in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The worldwide market for Sorafenib is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new study.
Market Segment by Manufacturers, this report covers
Bayer
Natco Pharma
Cipla
Mylan
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Patented Drugs
Generic Drugs
Market Segment by Applications, can be divided into
Kidney Cancer
Liver Cancer
Thyroid Cancer
Other
There are 15 Chapters to deeply display the global Sorafenib market.
Chapter 1, to describe Sorafenib Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Sorafenib, with sales, revenue, and price of Sorafenib, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Sorafenib, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Sorafenib market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Sorafenib sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Sorafenib Introduction
1.2 Market Analysis by Type
1.2.1 Patented Drugs
1.2.2 Generic Drugs
1.3 Market Analysis by Applications
1.3.1 Kidney Cancer
1.3.2 Liver Cancer
1.3.3 Thyroid Cancer
1.3.4 Other
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Bayer
2.1.1 Business Overview
2.1.1.1 Bayer Description
2.1.1.2 Bayer Headquarter, Main Business and Finance Overview
2.1.2 Bayer Sorafenib Product Introduction
2.1.2.1 Sorafenib Production Bases, Sales Regions and Major Competitors
2.1.2.2 Sorafenib Product Information
2.1.3 Bayer Sorafenib Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.1.3.1 Bayer Sorafenib Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.1.3.2 Global Bayer Sorafenib Market Share in 2017
2.2 Natco Pharma
2.2.1 Business Overview
2.2.1.1 Natco Pharma Description
2.2.1.2 Natco Pharma Headquarter, Main Business and Finance Overview
2.2.2 Natco Pharma Sorafenib Product Introduction
2.2.2.1 Sorafenib Production Bases, Sales Regions and Major Competitors
2.2.2.2 Sorafenib Product Information
2.2.3 Natco Pharma Sorafenib Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2.3.1 Natco Pharma Sorafenib Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2.3.2 Global Natco Pharma Sorafenib Market Share in 2017
2.3 Cipla
2.3.1 Business Overview
2.3.1.1 Cipla Description
2.3.1.2 Cipla Headquarter, Main Business and Finance Overview
2.3.2 Cipla Sorafenib Product Introduction
2.3.2.1 Sorafenib Production Bases, Sales Regions and Major Competitors
2.3.2.2 Sorafenib Product Information
2.3.3 Cipla Sorafenib Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3.3.1 Cipla Sorafenib Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3.3.2 Global Cipla Sorafenib Market Share in 2017
2.4 Mylan
2.4.1 Business Overview
2.4.1.1 Mylan Description
2.4.1.2 Mylan Headquarter, Main Business and Finance Overview
2.4.2 Mylan Sorafenib Product Introduction
2.4.2.1 Sorafenib Production Bases, Sales Regions and Major Competitors
2.4.2.2 Sorafenib Product Information
2.4.3 Mylan Sorafenib Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4.3.1 Mylan Sorafenib Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4.3.2 Global Mylan Sorafenib Market Share in 2017
3 Global Sorafenib Market Competition, by Manufacturer
3.1 Global Sorafenib Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Sorafenib Revenue and Market Share by Manufacturer (2016-2017)
3.3 Global Sorafenib Price by Manufacturer (2016-2017)
3.4 Market Concentration Rate
3.4.1 Top 3 Sorafenib Manufacturer Market Share in 2017
3.4.2 Top 5 Sorafenib Manufacturer Market Share in 2017
3.5 Market Competition Trend
4 Global Sorafenib Market Analysis by Regions
4.1 Global Sorafenib Sales, Revenue and Market Share by Regions
4.1.1 Global Sorafenib Sales by Regions (2013-2018)
4.1.2 Global Sorafenib Revenue by Regions (2013-2018)
4.2 North America Sorafenib Sales, Revenue and Growth Rate (2013-2018)
4.3 Europe Sorafenib Sales, Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Sorafenib Sales, Revenue and Growth Rate (2013-2018)
4.5 South America Sorafenib Sales, Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Sorafenib Sales, Revenue and Growth Rate (2013-2018)
5 North America Sorafenib by Countries, Type, Application and Manufacturers
5.1 North America Sorafenib Sales, Revenue and Market Share by Countries
5.1.1 North America Sorafenib Sales by Countries (2013-2018)
5.1.2 North America Sorafenib Revenue by Countries (2013-2018)
5.1.3 United States Sorafenib Sales and Growth Rate (2013-2018)
5.1.4 Canada Sorafenib Sales and Growth Rate (2013-2018)
5.1.5 Mexico Sorafenib Sales and Growth Rate (2013-2018)
5.2 North America Sorafenib Sales and Revenue (Value) by Manufacturers (2016-2017)
5.2.1 North America Sorafenib Sales by Manufacturers (2016-2017)
5.2.2 North America Sorafenib Revenue by Manufacturers (2016-2017)
5.3 North America Sorafenib Sales, Revenue and Market Share by Type (2013-2018)
5.3.1 North America Sorafenib Sales and Sales Share by Type (2013-2018)
5.3.2 North America Sorafenib Revenue and Revenue Share by Type (2013-2018)
5.4 North America Sorafenib Sales, Revenue and Market Share by Application (2013-2018)
5.4.1 North America Sorafenib Sales and Sales Share by Application (2013-2018)
5.4.2 North America Sorafenib Revenue and Revenue Share by Application (2013-2018)
6 Europe Sorafenib by Countries, Type, Application and Manufacturers
6.1 Europe Sorafenib Sales, Revenue and Market Share by Countries
6.1.1 Europe Sorafenib Sales by Countries (2013-2018)
6.1.2 Europe Sorafenib Revenue by Countries (2013-2018)
6.1.3 Germany Sorafenib Sales and Growth Rate (2013-2018)
6.1.4 UK Sorafenib Sales and Growth Rate (2013-2018)
6.1.5 France Sorafenib Sales and Growth Rate (2013-2018)
6.1.6 Russia Sorafenib Sales and Growth Rate (2013-2018)
6.1.7 Italy Sorafenib Sales and Growth Rate (2013-2018)
6.2 Europe Sorafenib Sales and Revenue (Value) by Manufacturers (2016-2017)
6.2.1 Europe Sorafenib Sales by Manufacturers (2016-2017)
6.2.2 Europe Sorafenib Revenue by Manufacturers (2016-2017)
6.3 Europe Sorafenib Sales, Revenue and Market Share by Type (2013-2018)
6.3.1 Europe Sorafenib Sales and Sales Share by Type (2013-2018)
6.3.2 Europe Sorafenib Revenue and Revenue Share by Type (2013-2018)
6.4 Europe Sorafenib Sales, Revenue and Market Share by Application (2013-2018)
6.4.1 Europe Sorafenib Sales and Sales Share by Application (2013-2018)
6.4.2 Europe Sorafenib Revenue and Revenue Share by Application (2013-2018)
7 Asia-Pacific Sorafenib by Countries, Type, Application and Manufacturers
7.1 Asia-Pacific Sorafenib Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Sorafenib Sales by Countries (2013-2018)
7.1.2 Asia-Pacific Sorafenib Revenue by Countries (2013-2018)
7.1.3 China Sorafenib Sales and Growth Rate (2013-2018)
7.1.4 Japan Sorafenib Sales and Growth Rate (2013-2018)
7.1.5 Korea Sorafenib Sales and Growth Rate (2013-2018)
7.1.6 India Sorafenib Sales and Growth Rate (2013-2018)
7.1.7 Southeast Asia Sorafenib Sales and Growth Rate (2013-2018)
7.2 Asia-Pacific Sorafenib Sales and Revenue (Value) by Manufacturers (2016-2017)
7.2.1 Asia-Pacific Sorafenib Sales by Manufacturers (2016-2017)
7.2.2 Asia-Pacific Sorafenib Revenue by Manufacturers (2016-2017)
7.3 Asia-Pacific Sorafenib Sales, Revenue and Market Share by Type (2013-2018)
7.3.1 Asia-Pacific Sorafenib Sales and Sales Share by Type (2013-2018)
7.3.2 Asia-Pacific Sorafenib Revenue and Revenue Share by Type (2013-2018)
7.4 Asia-Pacific Sorafenib Sales, Revenue and Market Share by Application (2013-2018)
7.4.1 Asia-Pacific Sorafenib Sales and Sales Share by Application (2013-2018)
7.4.2 Asia-Pacific Sorafenib Revenue and Revenue Share by Application (2013-2018)
8 South America Sorafenib by Countries, Type, Application and Manufacturers
8.1 South America Sorafenib Sales, Revenue and Market Share by Countries
8.1.1 South America Sorafenib Sales by Countries (2013-2018)
8.1.2 South America Sorafenib Revenue by Countries (2013-2018)
8.1.3 Brazil Sorafenib Sales and Growth Rate (2013-2018)
8.1.4 Argentina Sorafenib Sales and Growth Rate (2013-2018)
8.1.5 Colombia Sorafenib Sales and Growth Rate (2013-2018)
8.2 South America Sorafenib Sales and Revenue (Value) by Manufacturers (2016-2017)
8.2.1 South America Sorafenib Sales by Manufacturers (2016-2017)
8.2.2 South America Sorafenib Revenue by Manufacturers (2016-2017)
8.3 South America Sorafenib Sales, Revenue and Market Share by Type (2013-2018)
8.3.1 South America Sorafenib Sales and Sales Share by Type (2013-2018)
8.3.2 South America Sorafenib Revenue and Revenue Share by Type (2013-2018)
8.4 South America Sorafenib Sales, Revenue and Market Share by Application (2013-2018)
8.4.1 South America Sorafenib Sales and Sales Share by Application (2013-2018)
8.4.2 South America Sorafenib Revenue and Revenue Share by Application (2013-2018)
9 Middle East and Africa Sorafenib by Countries, Type, Application and Manufacturers
9.1 Middle East and Africa Sorafenib Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Sorafenib Sales by Countries (2013-2018)
9.1.2 Middle East and Africa Sorafenib Revenue by Countries (2013-2018)
9.1.3 Saudi Arabia Sorafenib Sales and Growth Rate (2013-2018)
9.1.4 UAE Sorafenib Sales and Growth Rate (2013-2018)
9.1.5 Egypt Sorafenib Sales and Growth Rate (2013-2018)
9.1.6 Nigeria Sorafenib Sales and Growth Rate (2013-2018)
9.1.7 South Africa Sorafenib Sales and Growth Rate (2013-2018)
9.2 Middle East and Africa Sorafenib Sales and Revenue (Value) by Manufacturers (2016-2017)
9.2.1 Middle East and Africa Sorafenib Sales by Manufacturers (2016-2017)
9.2.2 Middle East and Africa Sorafenib Revenue by Manufacturers (2016-2017)
9.3 Middle East and Africa Sorafenib Sales, Revenue and Market Share by Type (2013-2018)
9.3.1 Middle East and Africa Sorafenib Sales and Sales Share by Type (2013-2018)
9.3.1 Middle East and Africa Sorafenib Revenue and Revenue Share by Type (2013-2018)
9.4 Middle East and Africa Sorafenib Sales, Revenue and Market Share by Application (2013-2018)
9.4.1 Middle East and Africa Sorafenib Sales and Sales Share by Application (2013-2018)
9.4.2 Middle East and Africa Sorafenib Revenue and Revenue Share by Application (2013-2018)
10 Global Sorafenib Market Segment by Type
10.1 Global Sorafenib Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Sorafenib Sales and Market Share by Type (2013-2018)
10.1.2 Global Sorafenib Revenue and Market Share by Type (2013-2018)
10.2 Patented Drugs Sales Growth and Price
10.2.1 Global Patented Drugs Sales Growth (2013-2018)
10.2.2 Global Patented Drugs Price (2013-2018)
10.3 Generic Drugs Sales Growth and Price
10.3.1 Global Generic Drugs Sales Growth (2013-2018)
10.3.2 Global Generic Drugs Price (2013-2018)
11 Global Sorafenib Market Segment by Application
11.1 Global Sorafenib Sales Market Share by Application (2013-2018)
11.2 Kidney Cancer Sales Growth (2013-2018)
11.3 Liver Cancer Sales Growth (2013-2018)
11.4 Thyroid Cancer Sales Growth (2013-2018)
11.5 Other Sales Growth (2013-2018)
12 Sorafenib Market Forecast (2018-2023)
12.1 Global Sorafenib Sales, Revenue and Growth Rate (2018-2023)
12.2 Sorafenib Market Forecast by Regions (2018-2023)
12.2.1 North America Sorafenib Market Forecast (2018-2023)
12.2.2 Europe Sorafenib Market Forecast (2018-2023)
12.2.3 Asia-Pacific Sorafenib Market Forecast (2018-2023)
12.2.4 South America Sorafenib Market Forecast (2018-2023)
12.2.5 Middle East and Africa Sorafenib Market Forecast (2018-2023)
12.3 Sorafenib Market Forecast by Type (2018-2023)
12.3.1 Global Sorafenib Sales Forecast by Type (2018-2023)
12.3.2 Global Sorafenib Market Share Forecast by Type (2018-2023)
12.4 Sorafenib Market Forecast by Application (2018-2023)
12.4.1 Global Sorafenib Sales Forecast by Application (2018-2023)
12.4.2 Global Sorafenib Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Sorafenib Picture
Table Product Specifications of Sorafenib
Figure Global Sorafenib CAGR (%), Y-o-Y Growth (&) and Market Size, 2013-2023 (USD Million)